The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
Terlipressin and Octreotide are two common agents used as adjuvants in the management of
 variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in
 randomized studies. There are no head to head clinical trials of these two agents available
 in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide
 in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with
 Esophageal Variceal Bleed (EVB).
The effectiveness of combining Endoscopic treatment with Octreotide or Terlipressin has not
 been prospectively studied in esophageal variceal hemorrhage (EVH).

 This prospective, randomized clinical trial will help us in better patient management more
 efficiently and cost effectively.
Inclusion Criteria:

 -  All cirrhotic patients with upper GI bleed secondary to esophageal varices of 18 years
 or more of age

 Exclusion Criteria:

 -  Ulcerative esophagitis,

 -  Mallory Weiss tear,

 -  Bleeding gastric or duodenal ulcers,

 -  Bleeding from gastric varices or portal hypertensive gastropathy and

 -  Upper GI bleed as a result of thrombocytopenia or bleeding diathesis.